Skip to main content
Scot Remick, MD, Oncology, Scarborough, ME, Maine Medical Center

ScotCRemickMD

Oncology Scarborough, ME

Cancer Center Director at Mary Babb Randolph Cancer Center at West Virginia University

Dr. Remick is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Remick's full profile

Already have an account?

Education & Training

  • University of Wisconsin Hospitals and Clinics
    University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1985 - 1987
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1982 - 1985
  • New York Medical College
    New York Medical CollegeClass of 1982

Certifications & Licensure

  • ME State Medical License
    ME State Medical License 2015 - 2024
  • WV State Medical License
    WV State Medical License 2007 - 2017
  • OH State Medical License
    OH State Medical License 1996 - 2010
  • WI State Medical License
    WI State Medical License 1985 - 2007
  • NY State Medical License
    NY State Medical License 1988 - 1998
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2009-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • New Grant Will Broaden Access to Clinical Trials for Cancer Patients in Rural Maine
    New Grant Will Broaden Access to Clinical Trials for Cancer Patients in Rural MaineSeptember 5th, 2019
  • Briefs
    BriefsJune 11th, 2018
  • Expanding Access to Cutting Edge Cancer Care in Maine
    Expanding Access to Cutting Edge Cancer Care in MaineJuly 11th, 2017
  • Join now to see all

Grant Support

  • Developing Research Capacity For AIDS Malignancy In KenyaNational Cancer Institute2010–2011
  • Epothilone B Analogue BMS-247550 In PTS With Malignancies &Liver DysfunctionNational Center For Research Resources2006
  • 17-Allylamino-17 Demethoxygeldanamycin (17-Aag) W/Paclitaxel In Adv Solid TumorsNational Center For Research Resources2006
  • Foreign Accrual For 5u10ca062502 - Phase I U01 2006 Load RemickNational Cancer Institute2006
  • Combretastatin/Doxorubicin/Cisplatin For Patients With Thyroid CancerNational Center For Research Resources2005–2006
  • Combretastatin A-4 Phosphate In Advanced Anaplastic Thyroid CarcinomaNational Center For Research Resources2005–2006
  • Bryostatin 1 + Vincristine In Non-Hodgkin'S Lymphoma Post TransplantNational Center For Research Resources2005–2006
  • 17-Dimethylaminoethylamino-17demethoxygeldanamycin In Advanced Solid TumorsNational Center For Research Resources2005–2006
  • PS-341 In Patients With Advanced Malignancies And Renal DysfunctionNational Center For Research Resources2004–2006
  • Cwru/Uhicc Phase I Trials Of Anticancer AgentsNational Cancer Institute1998–2006
  • STI571 In Adv Malignancies Amp;Varying Degrees Of Renal DysfunctionNational Center For Research Resources2005
  • Silicone Phthalocyanine 4 (PC4) Photodynamic Therapy For Cutaneous MalignanciesNational Center For Research Resources2005
  • Fenretinide + Paclitaxel + Cisplatin For Advanced Solid TumorsNational Center For Research Resources2005
  • Epothilone B Analogue BMS-247550 In PTS With Malignancies And Liver DysfunctionNational Center For Research Resources2005
  • Thalidomide And Docetaxel For Advanced MalignanciesNational Center For Research Resources2004–2005
  • CCM AIDS Associated Malignancies Clinical Trials UnitNational Cancer Institute1999–2005
  • SU5416 And Paclitaxel In Recurrent Or Metastatic Carcinoma Of The Head And NeckNational Center For Research Resources2004
  • STI571 In PTS With Advanced Malignancies &Varying Levels Of Liver DysfunctionNational Center For Research Resources2004
  • STI571 In PTS With Advanced Malignancies &Varying Degrees Of Renal DysfunctionNational Center For Research Resources2004
  • Silicon Phthalocyanine 4 (PC4) + Photodynamic Therapy For Cutaneous MalignanciesNational Center For Research Resources2004
  • Oxaliplatin, Irinotecan, And Capecitabine In Solid TumorsNational Center For Research Resources2004
  • Combretastatin A-4 Phosphate In Advanced Anaplastic Carcinoma Of The ThyroidNational Center For Research Resources2004
  • Bryostatin 1+Vincristine In Non-Hodgkin'S Lymphoma PTS Post TransplantationNational Center For Research Resources2004
  • Oral Chemotherapy In Aids-Related NHL In Uganda &KenyaNational Cancer Institute2002–2003
  • Oxi 104 In Combination W/ Cisplatin In Patients W/ Advanced CancerNational Center For Research Resources1999–2002
  • CA4P (INTRAVENOUS) In Patients W/ Advanced CancerNational Center For Research Resources1999–2002
  • Bryostatin 1 &Vincristine In B Cell MalignanciesNational Center For Research Resources1999–2002
  • Core--InternationalNational Institute Of Allergy And Infectious Diseases1998–2002
  • Rebeccamycin Analog Given 5 Consecutive Days In Patients With Solid TumorsNational Center For Research Resources1998–2002
  • Oral Chemotherapy In AIDS Related NHL In Uganda &KenyaNational Cancer Institute2001
  • Core--Clinical Trials Support FacilityNational Cancer Institute1996–2000
  • Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1993–1996
  • Cooperative Oncology GroupNational Cancer Institute1994
  • Aids-Related CNS LymphomaNational Cancer Institute1993–1994
  • Eastern Cooperative Oncology GroupNational Cancer Institute1992–1993

Professional Memberships

Hospital Affiliations